The management of bleeding in patients with haemophilia with inhibitors is one of the most complex challenges in haemophilia therapy today. Although new treatment strategies have recently emerged, questions remain, including determining optimal dosing strategies for newer products and by-passing agents, and the need for new therapies in research that address the presence of inhibitors to Factors VIII and XI. This recorded CME symposium will provide a practical, evidence-based review of current clinical data for controlling bleeding in haemophilia with inhibitors, with a focus on applying emerging trial data to clinical practice.